Biogen   1Q Revenues: $2.6 billion (+20%) 1Q Earnings: $823 million (+71%) Comments: Total multiple sclerosis product sales were $2.1 billion compared to $1.7 billion in 1Q14. TECFIDERA revenues were $825 million, up 63%. Interferon revenues, including AVONEX and PLEGRIDY, were flat at $755 million. TYSABRI revenues were $463 million, up 5%. Revenues relating to RITUXAN and GAZYVA from Biogen’s unconsolidated joint business arrangement were $331 million, up 11%....